drugset / Trial / NCT07081633
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.
Timeline
- Start
- 2025-08-05
- Primary completion
- 2026-11-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Lenvatinib | Small molecule | — | Oral |
| Subject | Tremelimumab | Monoclonal antibody | — | Intravenous |